Emerging studies on retatrutide, a dual agonist for GLP-1 and glucose-dependent insulinotropic polypeptide, indicate significant findings in managing obesity and type 2 diabetes. Initial data from clinical trials reveal substantial decreases in body bulk and improved glucose levels. Ongoing examination is directed on long-term harmlessness and effe